Resource Type

Journal Article 718

Year

2023 33

2022 69

2021 60

2020 45

2019 70

2018 42

2017 42

2016 32

2015 43

2014 43

2013 38

2012 23

2011 29

2010 23

2009 32

2008 20

2007 20

2006 8

2005 2

2004 4

open ︾

Keywords

fuel cell 13

immunotherapy 8

prognosis 8

acute myeloid leukemia 7

leukemia 7

COVID-19 6

acute promyelocytic leukemia 6

hepatocellular carcinoma 6

solar cell 6

B-spline 5

biomarker 5

hematopoietic stem cell transplantation 5

hydrogen energy 5

stem cell 5

acute lymphoblastic leukemia 4

cell proliferation 4

control 4

hepatitis B virus 4

lung cancer 4

open ︾

Search scope:

排序: Display mode:

characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cellacute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients withrelapsed/refractory B-cell precursor acute lymphoblastic leukemia.and A-2019 are potent antitumor agents and capable of recruiting CD3 positive T cells, enhancing T-cellfunction, mediating B-cell depletion, and eventually inhibiting tumor growth in Raji xenograft models

Keywords: B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia

Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen

Frontiers of Medicine 2021, Volume 15, Issue 3,   Pages 347-371 doi: 10.1007/s11684-020-0821-6

Abstract: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic alterations withinhibitors (e.g., imatinib), immunomodulators, monoclonal antibodies, and chimeric antigen receptor T-cell

Keywords: BCP-ALL     subtypes     translocation     aneuploidy     sequence mutations    

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Abstract:

Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutelymphoblastic leukemia (B-ALL).This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblasticleukemia with poor prognosis.

Keywords: acute lymphoblastic leukemia     early T precursor     prognosis    

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 442-458 doi: 10.1007/s11684-021-0877-y

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hematological malignancies,We found that chidamide, an HDAC inhibitor, exerts an antitumor effect on T-ALL cell lines and primary

Keywords: T-cell acute lymphoblastic leukemia     HDAC inhibitor     chidamide     NOTCH1     MYC     ubiquitination    

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinicaland other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-T celltherapy for B-ALL, and daratumumab and nelarabine for T-ALL.

Keywords: acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 518-526 doi: 10.1007/s11684-022-0958-6

Abstract: Venous thromboembolism (VTE) is a complication in children with acute lymphoblastic leukemia (ALL).

Keywords: acute lymphoblastic leukemia     child     venous thromboembolism     epidemiology     clinical characteristic     risk    

Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 1-9 doi: 10.1007/s11684-015-0381-3

Abstract:

With the cure rate of childhood acute lymphoblastic leukemia (ALL) approaching 90%, further improvementpatients will require better understanding of the mechanisms of drug resistance, identifying new leukemic cellDeeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of leukemiasuch as early T-cell precursor ALL and Philadelphia chromosome-like ALL, and identified many genomic

Keywords: pharmacogenomics     acute lymphoblastic leukemia     genomics     pharmacogenetics    

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellCAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cellTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords: CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-cellthe causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell

Keywords: CAR T cells     hematological malignancies     review    

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation Article

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Engineering 2019, Volume 5, Issue 1,   Pages 150-155 doi: 10.1016/j.eng.2018.12.006

Abstract: cell transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL).Donor lymphoblastic infusion (DLI) is the main established approach to treat B-ALL with MRD after allo-HSCTThree of the six patients are currently alive without leukemia.No patient developed acute graft-versus-host disease (aGVHD), and no patient died of cytokine releasein B-ALL after allo-HSCT and for those who were not responsive to DLI.

Keywords: Donor-derived CD19-targeted T cell infusion     Hematopoietic stem cell transplantation     B cell acute lymphoblasticleukemia     Minimal residual disease    

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords: B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acutelymphoblastic leukemia

Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin

Frontiers of Medicine 2017, Volume 11, Issue 2,   Pages 229-238 doi: 10.1007/s11684-017-0506-y

Abstract:

A CALLG2008 protocol was developed by the Chinese Acute Lymphoblastic Leukemia Cooperative Group foradult acute lymphoblastic leukemia (ALL).Fifty-eight (36 with haploidentical donor) patients underwent allogeneic hematopoietic stem cell transplantation

Keywords: Philadelphia chromosome     acute lymphoblastic leukemia     imatinib     CALLG2008    

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Frontiers of Medicine   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50% long-term complete response in relapsed or refractory diffuse large B-cell lymphoma (DLBCLHowever, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellSingle-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected fromImmunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansion

Keywords: anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse

Yuting Tan,Han Liu,Saijuan Chen

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 412-420 doi: 10.1007/s11684-015-0423-x

Abstract:

Genetic mutations are considered to drive the development of acute myeloid leukemia (AML).mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia

Keywords: preleukemic stem cell     acute myeloid leukemia     relapse     DNMT3A    

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAcute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies.Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia

Keywords: acute myeloid leukemia     CAR T     immunotherapy    

Title Author Date Type Operation

characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cellacute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

Journal Article

Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia

Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen

Journal Article

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Journal Article

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese

Journal Article

Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acutelymphoblastic leukemia

Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Journal Article

Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse

Yuting Tan,Han Liu,Saijuan Chen

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article